# US 2021/0330614 A1 · Process for manufacturing phenylephrine resinate particles; phenylephrine resinate particles; and use of phenylephrine resinate particles in pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330614 A1
- Document ID: US20210330614A1
- Status: Published application
- Kind: A1
- Application number: 17/343,169
- Filed: 2021-06-09
- Published: 2021-10-28
- Earliest claimed: 2014-12-12
- Assignees: Johnson & Johnson Consumer Inc.
- Applicants: Johnson & Johnson Consumer Inc.
- Inventors: Vincent W. Chen; Shun-Por Li; Edward A. Koch; Der-Yang Lee; Joel Waldman
- Web page: https://patentgrep.com/patent/US20210330614A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A process for preparing a drug-resin complex, comprising:
Step A:
mixing purified water and resin in a container to form a first mixture;
filtering the first mixture to form a wet cake containing resin;
rinsing the wet cake containing resin with purified water;
filtering the rinsed wet cake containing resin;
Step B:
mixing purified drug and water in a container to form a drug solution;
Step C:
mixing the filtered wet cake containing resin and a portion of the drug solution in a container to form a second mixture;
filtering the second mixture to form a first loaded resinate;
Step D:
mixing the first loaded resinate and a portion of the drug solution in a container to form a third mixture;
filtering the third mixture to form a second loaded resinate;
Step E:
optionally, repeating step D multiple times; and
Step F:
drying the loaded resinate to form the drug-resin complex.

### Claim 20 (depends on 19)

The process of claim 19, wherein the drug is phenylephrine.

### Claim 21 (depends on 20)

The process of claim 20, wherein the resin is a cation polystyrene sulfonate.

### Claim 22 (depends on 21)

The process of claim 21, wherein the cation polystyrene sulfonate comprises particle sizes of about 74 μm to about 177 μm prior to being combined with the phenylephrine.

### Claim 23 (depends on 22)

The process of claim 22, wherein the drug resin complex comprises phenylephrine:resin in a ratio of greater than about 1:1.

### Claim 24 (depends on 23)

The process of claim 23, wherein the drug resin complex comprises phenylephrine:resin in a ratio of about 1.4:1.
